Update shared on 30 Nov 2025
Fair value Increased 2.24%Analysts have raised their fair value estimate for Adaptive Biotechnologies to $19.57 from $19.14. They cite increased confidence in the company's sustained revenue growth and leadership position in cancer testing.
Analyst Commentary
Recent research notes highlight a range of perspectives regarding Adaptive Biotechnologies’ valuation, market position, and growth outlook. Analysts have considered both the company's strengths and ongoing challenges as they adjust their price targets and recommendations following recent earnings and market developments.
Bullish Takeaways
- Bullish analysts cite Adaptive Biotechnologies' position as a leader in blood cancer testing, particularly its dominance in the minimal residual disease space.
- They see strong prospects for continued revenue growth, supported by expanding market conversion, entry into new indications, and the potential for price increases.
- Some believe the current valuation represents a notable discount compared to other leading cancer specialty laboratory companies, suggesting future upside potential.
- Upward price target revisions reflect increased confidence in Adaptive’s ability to sustain momentum and execute effectively on its commercial strategy.
Bearish Takeaways
- Bearish analysts maintain a cautious stance, with some keeping more neutral ratings despite acknowledging operational progress.
- Concerns remain about whether market expansion and revenue acceleration can be sustained over the longer term, especially in a competitive diagnostic landscape.
- There is ongoing scrutiny on the company’s ability to maintain its leadership position as competitors innovate and enter the cancer testing market.
What's in the News
- Adaptive Biotechnologies raised its full-year 2025 revenue guidance for its MRD (minimal residual disease) business to between $202 million and $207 million, up from a prior range of $190 million to $200 million (Key Developments).
- No updated revenue guidance was provided for the Immune Medicine business in the company’s latest statement (Key Developments).
Valuation Changes
- Fair Value Estimate has risen slightly, from $19.14 to $19.57 per share.
- Discount Rate has decreased modestly, shifting from 7.94% to 7.91%.
- Revenue Growth Forecast has edged down minimally, moving from 14.01% to 13.95%.
- Net Profit Margin projection has dipped from 15.70% to 15.51%.
- Future P/E Ratio estimate has increased slightly, from 68.81x to 69.95x.
Have other thoughts on Adaptive Biotechnologies?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.